Share This Page
Drug Price Trends for MS CONTIN ER
✉ Email this page to a colleague
Average Pharmacy Cost for MS CONTIN ER
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
MS CONTIN ER 30 MG TABLET | 42858-0631-01 | 8.32796 | EACH | 2024-12-18 |
MS CONTIN ER 30 MG TABLET | 42858-0631-01 | 8.32796 | EACH | 2024-11-20 |
MS CONTIN ER 15 MG TABLET | 42858-0515-01 | 4.40368 | EACH | 2024-06-03 |
MS CONTIN ER 30 MG TABLET | 42858-0631-01 | 8.38027 | EACH | 2024-06-03 |
MS CONTIN ER 15 MG TABLET | 42858-0515-01 | 4.04004 | EACH | 2024-05-22 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
MS CONTIN ER Market Analysis and Financial Projection
Market Analysis and Price Projections for MS CONTIN ER
Overview of MS CONTIN ER
MS CONTIN ER, or Morphine Sulfate Controlled-Release Tablets, is a long-acting opioid formulation designed for the management of moderate to severe pain that requires continuous, around-the-clock opioid analgesia. This medication is particularly indicated for opioid-tolerant patients and is not intended for use as a PRN (as needed) analgesic or for pain in the immediate postoperative period[3].
Market Size and Growth
The global opioids market, which includes MS CONTIN ER, was valued at approximately USD 22.8 billion in 2022. This market is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 1.4% from 2023 to 2030. The extended-release (ER)/long-acting opioids segment, where MS CONTIN ER falls, accounted for the largest revenue share of 54.2% in 2022 and is expected to grow at a CAGR of 1.7% during the forecast period[4].
Regional Market Share
North America currently leads the global opioids market with the highest market share, accounting for approximately 45.13% in 2023. However, the Asia-Pacific region is expected to expand at the fastest CAGR during the forecast period, driven by increasing healthcare expenditure and a growing patient population[1].
Application and Usage
MS CONTIN ER is primarily used for pain relief, which is the largest application segment within the opioids market. The pain relief segment held a significant market share of 24% in 2023. Additionally, the anesthesia segment, where opioids like MS CONTIN ER are used to provide analgesia and supplement sedation during general anesthesia, is expected to grow at a CAGR of 2.0% over the forecast period[1][4].
Route of Administration
The oral route of administration, which includes MS CONTIN ER tablets, is a significant segment within the opioids market. While the injectable segment currently holds the largest revenue share, the oral segment is anticipated to grow at a CAGR of 2.1% to 2.5% over the forecast period, driven by the approval of new opioid tablets and formulations[1][4].
Pricing and Cost Analysis
The cost of MS CONTIN ER varies based on the dosage and the pharmacy. Here are some approximate prices for different strengths of MS CONTIN ER:
- 15 mg/8 to 12 hr: Around $492.68 for 100 tablets
- 30 mg/8 to 12 hr: Around $927.65 for 100 tablets
- 60 mg/8 to 12 hr: Around $1,801.07 for 100 tablets
- 100 mg/8 to 12 hr: Around $2,662.03 for 100 tablets
- 200 mg/8 to 12 hr: Around $4,867.31 for 100 tablets[2].
These prices are subject to variations due to stock shortages and other market factors.
Distribution Channels
The retail pharmacy segment leads the market with the maximum market share of 38% in 2023. This segment is expected to continue its dominance, although other distribution channels, such as online pharmacies, are also growing[1].
Competitive Landscape
The opioids market is highly competitive, with several key players including pharmaceutical companies like Teva, which has been involved in significant settlements and market movements. For instance, in January 2023, Teva announced a nationwide opioids settlement, which reflects the complex legal and regulatory environment surrounding opioids[1].
Regulatory Environment
The regulatory environment for opioids is stringent due to concerns about abuse and addiction. For example, the FDA has approved various abuse-deterrent formulations, and there are regulations requiring pharmacists to substitute high-potency, high-risk (HPHR) opioids with abuse-deterrent opioids (ADOs) when possible[5].
Future Outlook
Given the growing demand for effective pain management solutions, particularly in acute and chronic pain settings, the market for ER/long-acting opioids like MS CONTIN ER is expected to continue growing. Advancements in pharmacokinetics and patient-centric treatment approaches are driving this growth. However, the market will also be influenced by regulatory changes, legal settlements, and the ongoing need to balance pain management with opioid safety and abuse prevention.
Key Takeaways
- Market Growth: The global opioids market, including MS CONTIN ER, is expected to grow at a CAGR of 1.4% from 2023 to 2030.
- Regional Dominance: North America currently leads the market, but the Asia-Pacific region is expected to grow at the fastest CAGR.
- Application: Pain relief is the primary application, with the anesthesia segment also showing significant growth.
- Route of Administration: Oral formulations like MS CONTIN ER are expected to grow at a CAGR of 2.1% to 2.5%.
- Pricing: Prices vary by dosage and pharmacy, with significant costs associated with higher strengths.
- Distribution: Retail pharmacies dominate the distribution channels.
- Regulatory Environment: Stringent regulations and the need for abuse-deterrent formulations are key factors.
FAQs
1. What is MS CONTIN ER used for? MS CONTIN ER is used for the management of moderate to severe pain that requires continuous, around-the-clock opioid analgesia, particularly in opioid-tolerant patients.
2. How is the global opioids market expected to grow? The global opioids market is expected to grow at a CAGR of 1.4% from 2023 to 2030, with the ER/long-acting opioids segment growing at a CAGR of 1.7%.
3. What is the current market share of North America in the opioids market? North America currently holds the highest market share of approximately 45.13% in the global opioids market.
4. How does the pricing of MS CONTIN ER vary? The pricing of MS CONTIN ER varies significantly based on the dosage strength, ranging from around $492.68 for 100 tablets of the 15 mg strength to around $4,867.31 for 100 tablets of the 200 mg strength.
5. What are the key distribution channels for MS CONTIN ER? The retail pharmacy segment leads the market with the maximum market share, although other distribution channels are also growing.
Sources
- Biospace: Opioids Market Size to Worth Around USD 26.78 Billion by 2034
- Drugs.com: MS Contin Prices, Coupons, Copay Cards & Patient Assistance
- FDA: MS CONTIN (morphine sulfate controlled-release) Tablets CII
- Grandview Research: Opioids Market Size, Share & Growth Analysis Report, 2030
- Mass.gov: Actuarial Analysis of the Drug Formulary Commission's Abuse Deterrent Drug Formulary
More… ↓